Effects of Hemodialysis Combined with Hemoperfusion on Glycolipid Me-tabolism and Coagulation Function in Patients with End-stage Diabetic Ne-phropathy
Objective To explore the effects of hemodialysis combined with hemoperfusion on glycolipid metabolism and coagulation function in patients with end-stage diabetic nephropathy.Methods The clinical data of 70 patients with end-stage diabetic nephropathy 2021 admitted to the First People's Hospital of Tianshui from September to May 2022 were retrospectively selected.They were divided into two groups according to different treatment with 35 cases in each group.The control group was given hemodialysis,the research group was given hemodialysis and hemoperfu-sion.The glucolipid metabolism,coagulation function and clinical efficacy of the two groups were compared.Results There was no significant difference in glucolipid metabolism between the two groups before treatment.After treatment,the level of fasting plasma glucose(FPG)in the study group was(9.46±0.75)mmol/l,which was significantly lower than that in the control group(10.23±1.32)mmol/L,the difference was statistically significant(P<0.05).After treat-ment,the level of glycosylated hemoglobin A1c(HbA1c)in both groups was significantly lower,the level of HbA1c in the study group(7.08±1.05)%was significantly lower than that in the control group(8.04±1.30)%,and the level of tri-glyceride was lower than that of control group,the differences were statistically significant(both P<0.05).After treat-ment,activated partial thromboplatin time(APTT),thrombin time(TT),prothrombin time(PT)were shorter and fibrino-gen(FIB)were significantly increased in both groups,and PT,TT and APTT were shorter in the study group as com-pared with those in the control group,FIB was significantly higher than that of the control group,the differences were statistically significant(all P<0.05).The total effective rate of treatment the study group was 97.14%,which was sig-nificantly higher than that of the control group(82.86%),and the difference was statistically significant(χ2=3.968,P<0.05).Conclusion Combined treatment for end-stage renal disease can effectively improve patients'glucose-lipid me-tabolism and coagulation function,reduce side effects.
HemodialysisHemoperfusionEnd-stage diabetic nephropathyGlycolipid metabolismCoagulation function
NETL
NSTL
万方数据
